NCT00217373View on ClinicalTrials.gov

Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

January 31, 2013

Study Completion Date

March 31, 2015

Conditions
Adult Solid Neoplasm
Interventions
BIOLOGICAL

Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine

Given SC

BIOLOGICAL

Recombinant Interferon Alfa-2b

Given SC

BIOLOGICAL

Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine

Given SC

BIOLOGICAL

Sargramostim

Given SC

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00217373 - Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) | Biotech Hunter | Biotech Hunter